Stockreport

Atea Pharmaceuticals' COVID-19 Treatment Flunks In Late-Stage Study, Blames 'Constantly Evolving' Virus [Yahoo! Finance]

Atea Pharmaceuticals, Inc. - common stock  (AVIR) 
PDF global Phase 3 SUNRISE-3 trial evaluating bemnifosbuvir, an oral nucleotide polymerase inhibitor, versus placebo for COVID-19 The trial did not meet the primary endpoi [Read more]